跳至主要内容
临床试验/ACTRN12616000741482
ACTRN12616000741482已完成未知

A randomised placebo controlled clinical trial on the efficacy of Caralluma supplement for anxiety and stress in healthy adults over eight weeks

RDC Global0 个研究点目标入组 117 人开始时间: 2016年6月6日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
RDC Global
入组人数
117

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • Participants will be included for assessment if they self-report mild-moderate anxiety (BAI >9<30), are not diagnosed with depression or a mood disorder, are otherwise healthy, and have given written informed consent.

排除标准

  • Participants will be excluded if they:
  • have a known hypersensitivity to herbal drugs, or nutritional supplements;
  • have been diagnosed with hypertension and are receiving medication;
  • have a medical condition which, in the opinion of the investigator, makes them unsuitable or deemed unhealthy (including a BMI > 30);
  • have currently or have a history of chronic alcohol and/or drug abuse;
  • have participated in any other clinical trial during last 30 days;
  • are currently participating in another clinical trial;
  • have been diagnosed with a mood disorder;
  • have minimal or severe anxiety on the Beck Anxiety Inventory (<10, or > 29);
  • suffered severe PMS with mood or pain that would change during the study;
  • suffered from any neurological disorder;
  • are taking supplements that impact mood or appetite (e.g., St John’s Wort, leptin);
  • are already taking Caralluma.

研究者

发起方
RDC Global

相似试验